Related Experiment Video
Updated: Feb 19, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
Published on: March 3, 2015
High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and
Yun Hua1, Daniel P Camarco1, Christopher J Strock2
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Room 586 Salk Hall, 3501 Terrace Street, Pittsburgh, PA, 15261, USA.
Abstract:
Transcriptional Intermediary Factor 2 (TIF2) is a key Androgen receptor (AR) coactivator that has been implicated in the development and progression of castration resistant prostate cancer (CRPC). This chapter describes the implementation of an AR-TIF2 protein-protein interaction (PPI) biosensor assay to screen for small molecules that can induce AR-TIF2 PPIs, inhibit the DHT-induced formation of AR-TIF2 PPIs, or disrupt pre-existing AR-TIF2 PPIs. The biosensor assay employs high content imaging and analysis to quantify AR-TIF2 PPIs and integrates physiologically relevant cell-based assays with the specificity of binding assays by incorporating structural information from AR and TIF2 functional domains along with intracellular targeting sequences using fluorescent protein reporters. Expression of the AR-Red Fluorescent Protein (RFP) "prey" and TIF2-Green Fluorescent Protein (GFP) "bait" components of the biosensor is directed by recombinant adenovirus (rAV) expression constructs that facilitated a simple co-infection protocol to produce homogeneous expression of both biosensors that is scalable for screening. In untreated cells, AR-RFP expression is localized predominantly to the cytoplasm and TIF2-GFP expression is localized only in the nucleoli of the nucleus. Exposure to DHT induces the co-localization of AR-RFP within the TIF2-GFP positive nucleoli of the nucleus. The AR-TIF2 biosensor assay therefore recapitulates the ligand-induced translocation of latent AR from the cytoplasm to the nucleus, and the PPIs between AR and TIF2 result in the colocalization of AR-RFP within TIF2-GFP expressing nucleoli. The AR-TIF2 PPI biosensor approach offers significant promise for identifying molecules with potential to modulate AR transcriptional activity in a cell-specific manner that may overcome the development of resistance and progression to CRPC.
Insights
A new biosensor assay screens for drugs targeting the Androgen Receptor (AR) and Transcriptional Intermediary Factor 2 (TIF2) interaction, crucial in prostate cancer progression. This method identifies compounds that modulate AR-TIF2 interactions to combat castration-resistant prostate cancer (CRPC).
Area of Science:
- Molecular Biology
- Biochemistry
- Oncology
Background:
- Transcriptional Intermediary Factor 2 (TIF2) is a key coactivator for the Androgen Receptor (AR).
- AR-TIF2 interactions are implicated in the development and progression of castration-resistant prostate cancer (CRPC).
- Targeting AR-TIF2 interactions offers a potential therapeutic strategy for CRPC.
Purpose of the Study:
- To develop and implement a biosensor assay for screening small molecules targeting AR-TIF2 protein-protein interactions (PPIs).
- To identify compounds that can induce, inhibit, or disrupt AR-TIF2 PPIs.
- To provide a cell-based, scalable screening method for potential CRPC therapeutics.
Main Methods:
- Development of an AR-TIF2 protein-protein interaction (PPI) biosensor using fluorescent protein reporters (AR-RFP and TIF2-GFP).
- Utilized high-content imaging and analysis to quantify AR-TIF2 PPIs.
- Employed recombinant adenovirus (rAV) for homogeneous and scalable expression of biosensor components.
Main Results:
- The biosensor assay successfully recapitulates ligand-induced AR translocation and AR-TIF2 complex formation.
- AR-RFP co-localizes with TIF2-GFP in nucleoli upon Dihydrotestosterone (DHT) exposure, indicating successful AR-TIF2 interaction.
- The assay is scalable and suitable for high-throughput screening.
Conclusions:
- The AR-TIF2 PPI biosensor is a promising tool for identifying modulators of AR transcriptional activity.
- This approach may lead to novel therapeutics that overcome resistance mechanisms in CRPC.
- Cell-specific modulation of AR activity offers a targeted strategy against prostate cancer progression.
More Related Videos
06:43A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents
Published on: August 31, 2013
08:21Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019